Drug Trial Radar · NCT07321093
A Study of the Efficacy and Safety of BCD-281 in Patients With Relapsing-Remitting Multiple Sclerosis
Last checked: Nov 19, 2026Latest source record: Jan 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
292
Planned (sponsor's estimate)
Start
Nov 1, 2025
Primary completion
Dec 2028
Study completion Dec 2028
Sponsor
- Lead sponsor
- BiocadIndustry
- Sponsor type
- Industry
- First posted
- Jan 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of this study is to compare the efficacy, safety profile, pharmacokinetics, pharmacodynamics, and immunogenicity of BCD-281 and the reference drug in subjects with relapsing multiple sclerosis.
Conditions
- Relapsing-remitting Multiple Sclerosis (RRMS)
Interventions
BCD-281Biological
anti-CD20 monoclonal antibody
OcrelizumabBiological
anti-CD20 monoclonal antibody
Primary outcomes
What the sponsor says the trial is designed to measure.
- Total number of T1 gadolinium-enhancing (Gd+) lesions up to Week 24.Time frame: up to Week 24
Locations
1 site in 1 country. Site status is shown where the registry gives one.
LLC "Medis"
Nizhny Novgorod, Russia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.